Clinical pharmacogenetics and future prospects in drug therapy

Research output: Contribution to journalReview article

Abstract

The human genome project has a large impact on various drug-related fields including drug discovery and clinical medication. Although clinical pharmacogenetics introduced the importance of studying genetic factors determining inter-individual variation on drug response for establishing a personalized medicine, which will be achieved in this century, recent strategies for exploring the genetic factors drastically differ from those of classical pharmacogenetics. The usefulness of an application of findings obtained from basic researches to a medication is uncertain at present because of limited in vivo evidence on the significance of genetic polymorphism to ensure an efficacy or to avoid adverse reactions of the drugs. In this review, a brief history of pharmacogenetics and the current status of the research are summarized. A number of problems that make it difficult to do clinical trials to clarify the significance of genetic polymorphism are discussed. Finally, it is expected in the near future that information on genetic variation with in silico technologies may predict the response toward drugs in each patient with various physiological and therapeutic conditions.

Original languageEnglish
Pages (from-to)181-186
Number of pages6
JournalFolia Pharmacologica Japonica
Volume120
Issue number3
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Pharmacogenetics
Genetic Polymorphisms
Drug Therapy
Pharmaceutical Preparations
Human Genome Project
Precision Medicine
Drug Discovery
Drug-Related Side Effects and Adverse Reactions
Research
Computer Simulation
Clinical Trials
Technology
Therapeutics

Keywords

  • Cytochrome P450 (CYP)
  • Drug metabolizing enzyme
  • Drug response
  • Genetic polymorphism
  • Single nucleotide polymorphism (SNPs)

ASJC Scopus subject areas

  • Pharmacology

Cite this

Clinical pharmacogenetics and future prospects in drug therapy. / Ariyoshi, Noritaka.

In: Folia Pharmacologica Japonica, Vol. 120, No. 3, 2002, p. 181-186.

Research output: Contribution to journalReview article

@article{cd6b0db116d04deabb991f321c7c9d5d,
title = "Clinical pharmacogenetics and future prospects in drug therapy",
abstract = "The human genome project has a large impact on various drug-related fields including drug discovery and clinical medication. Although clinical pharmacogenetics introduced the importance of studying genetic factors determining inter-individual variation on drug response for establishing a personalized medicine, which will be achieved in this century, recent strategies for exploring the genetic factors drastically differ from those of classical pharmacogenetics. The usefulness of an application of findings obtained from basic researches to a medication is uncertain at present because of limited in vivo evidence on the significance of genetic polymorphism to ensure an efficacy or to avoid adverse reactions of the drugs. In this review, a brief history of pharmacogenetics and the current status of the research are summarized. A number of problems that make it difficult to do clinical trials to clarify the significance of genetic polymorphism are discussed. Finally, it is expected in the near future that information on genetic variation with in silico technologies may predict the response toward drugs in each patient with various physiological and therapeutic conditions.",
keywords = "Cytochrome P450 (CYP), Drug metabolizing enzyme, Drug response, Genetic polymorphism, Single nucleotide polymorphism (SNPs)",
author = "Noritaka Ariyoshi",
year = "2002",
doi = "10.1254/fpj.120.181",
language = "English",
volume = "120",
pages = "181--186",
journal = "Folia Pharmacologica Japonica",
issn = "0015-5691",
publisher = "Japanese Pharmacological Society",
number = "3",

}

TY - JOUR

T1 - Clinical pharmacogenetics and future prospects in drug therapy

AU - Ariyoshi, Noritaka

PY - 2002

Y1 - 2002

N2 - The human genome project has a large impact on various drug-related fields including drug discovery and clinical medication. Although clinical pharmacogenetics introduced the importance of studying genetic factors determining inter-individual variation on drug response for establishing a personalized medicine, which will be achieved in this century, recent strategies for exploring the genetic factors drastically differ from those of classical pharmacogenetics. The usefulness of an application of findings obtained from basic researches to a medication is uncertain at present because of limited in vivo evidence on the significance of genetic polymorphism to ensure an efficacy or to avoid adverse reactions of the drugs. In this review, a brief history of pharmacogenetics and the current status of the research are summarized. A number of problems that make it difficult to do clinical trials to clarify the significance of genetic polymorphism are discussed. Finally, it is expected in the near future that information on genetic variation with in silico technologies may predict the response toward drugs in each patient with various physiological and therapeutic conditions.

AB - The human genome project has a large impact on various drug-related fields including drug discovery and clinical medication. Although clinical pharmacogenetics introduced the importance of studying genetic factors determining inter-individual variation on drug response for establishing a personalized medicine, which will be achieved in this century, recent strategies for exploring the genetic factors drastically differ from those of classical pharmacogenetics. The usefulness of an application of findings obtained from basic researches to a medication is uncertain at present because of limited in vivo evidence on the significance of genetic polymorphism to ensure an efficacy or to avoid adverse reactions of the drugs. In this review, a brief history of pharmacogenetics and the current status of the research are summarized. A number of problems that make it difficult to do clinical trials to clarify the significance of genetic polymorphism are discussed. Finally, it is expected in the near future that information on genetic variation with in silico technologies may predict the response toward drugs in each patient with various physiological and therapeutic conditions.

KW - Cytochrome P450 (CYP)

KW - Drug metabolizing enzyme

KW - Drug response

KW - Genetic polymorphism

KW - Single nucleotide polymorphism (SNPs)

UR - http://www.scopus.com/inward/record.url?scp=0036368093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036368093&partnerID=8YFLogxK

U2 - 10.1254/fpj.120.181

DO - 10.1254/fpj.120.181

M3 - Review article

VL - 120

SP - 181

EP - 186

JO - Folia Pharmacologica Japonica

JF - Folia Pharmacologica Japonica

SN - 0015-5691

IS - 3

ER -